Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16

International Journal of Cancer

Volumn 67, Issue 3, 1996, Pages 435-440

  Naito, Mikihiko ^a   Watanabe, Toru ^b   Tsuge, Harumi ^a   Koyama, Tomoko ^a   Oh Hara, Tomoko ^c   Tsuruo, Takashi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b Sandoz Pharmaceuticals   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MRK 16; UNCLASSIFIED DRUG; VALSPODAR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0029787290     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19960729)67:3<435::aid-ijc20>3.3.co;2-%23     Document Type: Article

References (29)

1. ARCHINAL-MATTHEIS, A., RZEPKA, R.W., WATANABE, T., KOKUBU, N., ITOH, Y., COMBATES, N.J., BAIR, K.W. and COHEN, D., Analysis of the interaction of SDZ PSC 833 ([3′-keto-Bmt1]-Val2]-cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol. Res., 7, 603-610 (1995).
2. BERENBAUM, M.C., Criteria for analyzing interactions between biologically active agents. In: G. Klein and W. Weinhouse (eds.), Advances in Cancer Research. Vol. 35, pp. 269-335, Academic Press, New York (1981).
3. BOESCH, D., GAVERIAUX, C., JACHEZ, B., POURTIER-MANZANEDO, A., BOLLINGER, P. and LOOR, F., In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233 (1991a).
4. BOESCH, D., MULLER, K., POURTIER-MANZANEDO, A. and LOOR, F., Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivatives. Exp. Cell Res., 196, 26-32 (1991a).
5. ENDICOTT, J.A. and LING, V., The biochemistry of P-glycoproteinmediated multidrug resistance. Ann. Rev. Biochem., 58, 137-171 (1989).
6. HAMADA, H. and TSURUO, T., Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. nat. Acad. Sci. (Wash.), 83, 7785-7789 (1986).
7. HEIKE, Y., HAMADA, H., INAMURA, N., SONE, S., OGURA, T. and TSURUO, T., Monoclonal anti-P-glycoprotein antibody-dependent killing of multidrug-resistant tumor cells by human mononuclear cells. Jpn. J. Cancer Res., 81, 1155-1161 (1990).
8. KELLER, R.P., ALTERMATT, H.J., DONATSCH, P., ZIHLMANN, H., LAISSUE, J.A. and HIESTAND, P.C., Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer, 51, 433-438 (1992a).
9. KELLER, R.P., ALTERMATT, H.J., NOOTER, K., POSCHMAN, G., LAISSUE, J.A., BOLLINGER, P. and HIESTAND, P.C., SDZ PSC 833, a nonimmunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50, 593-597 (1992b).
10. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J. biol. Chem., 263, 11887-11891 (1988).
11. NAITO, M., OH-HARA, T., YAMAZAKI, A., DANKI, T. and TSURUO, T., Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol., 29, 195-200 (1992).
12. NAITO, M., TSUGE, H., KUROKO, C., KOYAMA, T., TOMIDA, A., TATSUTA, T., HEIKE, Y. and TSURUO, T., Enhancement of cellular accumulation of cyclosporin A by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance, J. nat. Cancer Inst., 85, 311-316 (1993a).
13. NAITO, M., TSUGE, H., KUROKO, C., TOMIDA, A. and TSURUO, T., Enhancement of reversing effect of cyclosporin A on vincristine resistance by anti-P-glycoprotein monoclonal antibody MRK-16. Jpn. J. Cancer Res., 84, 489-492 (1993b).
14. NAITO, M. and TSURUO, T., Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res., 49, 1452-1455 (1989).
15. PASTAN, I. and GOTTESMAN, M.M., Multiple-drug resistance in human cancer. N. Engl. J. Med., 316, 1388-1393 (1987).
16. ROGAN, A.M., HAMILTON, T.C., YOUNG, R.C., KLECKER, R.W.J. and OZOLS, R.F., Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science, 224, 994-996 (1984).
17. SAEKI, T., UEDA, K., TANIGAWARA, Y., HORI, R. and KOMANO, T., Human P-glycoprotein transports cyclosporin A and FK-506. J. biol. Chem., 268, 6077-6080 (1993).
18. SHIRAI, A., NAITO, M., TATSUTA, T., DONG, J., HANAOKA, K., MIKAMI, K., OH-HARA, T. and TSURUO, T., Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim. biophys. Acta, 1222, 400-404 (1994).
19. SLATER, L.M., SWEET, P., STUPECKY, M. and GUPTA, S., Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. clin. Invest., 77, 1405-1408 (1986a).
20. SLATER, L.M., SWEET, P., STUPECKY, M., WETZEL, M.W. and GUPTA, S., Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Brit. J. Cancer, 54, 235-238 (1986b).
21. TAMAI, I. and SAFA, A.R., Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J. biol. Chem., 265, 16509-16513 (1990).
22. TSURUO, T., Mechanism of multidrug resistance and implications for therapy. Jpn. J. Cancer Res., 79, 285-296 (1988).
23. TSURUO, T., HAMADA, H., SATO, S. and HEIKE, Y., Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn. J. Cancer Res., 80, 627-631 (1989).
24. TSURUO, T., IIDA, H., TSUKAGOSHI, S. and SAKURAI, Y., Increased accumulation of vincristine and Adriamycin in drug-resistant tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res., 42, 4730-4733 (1982).
25. TSURUO, T., IIDA, H., TSUKAGOSHI, S. and SAKURAI, Y., Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967-1972 (1981).
26. TSURUO, T., IIDA-SAITO, H., KAWABATA, H., OH-HARA, T., HAMADA, H. and UTAKOJI, T., Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and in isolated clones. Jpn. J. Cancer Res., 77, 682-692 (1986).
27. TWENTYMAN, P.R., Modification of cytotoxic drug resistance by nonimmuno-suppressive cyclosporins. Brit. J. Cancer, 57, 254-258 (1988).
28. WATANABE, T., TSUGE, H., OH-HARA, T., NAITO, M. and TSURUO, T., Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol., 34, 235-241 (1995).
29. YUSA, K. and TSURUO, T., Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res., 49, 5002-5006 (1989).